Unknown

Dataset Information

0

Fructose-1,6-Bisphosphatase 2 Inhibits Sarcoma Progression by Restraining Mitochondrial Biogenesis.


ABSTRACT: The remarkable cellular and genetic heterogeneity of soft tissue sarcomas (STSs) limits the clinical benefit of targeted therapies. Here, we show that expression of the gluconeogenic isozyme fructose-1,6-bisphosphatase 2 (FBP2) is silenced in a broad spectrum of sarcoma subtypes, revealing an apparent common metabolic feature shared by diverse STSs. Enforced FBP2 expression inhibits sarcoma cell and tumor growth through two distinct mechanisms. First, cytosolic FBP2 antagonizes elevated glycolysis associated with the "Warburg effect," thereby inhibiting sarcoma cell proliferation. Second, nuclear-localized FBP2 restrains mitochondrial biogenesis and respiration in a catalytic-activity-independent manner by inhibiting the expression of nuclear respiratory factor and mitochondrial transcription factor A (TFAM). Specifically, nuclear FBP2 colocalizes with the c-Myc transcription factor at the TFAM locus and represses c-Myc-dependent TFAM expression. This unique dual function of FBP2 provides a rationale for its selective suppression in STSs, identifying a potential metabolic vulnerability of this malignancy and possible therapeutic target.

SUBMITTER: Huangyang P 

PROVIDER: S-EPMC6949384 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Fructose-1,6-Bisphosphatase 2 Inhibits Sarcoma Progression by Restraining Mitochondrial Biogenesis.

Huangyang Peiwei P   Li Fuming F   Lee Pearl P   Nissim Itzhak I   Weljie Aalim M AM   Mancuso Anthony A   Li Bo B   Keith Brian B   Yoon Sam S SS   Simon M Celeste MC  

Cell metabolism 20191121 1


The remarkable cellular and genetic heterogeneity of soft tissue sarcomas (STSs) limits the clinical benefit of targeted therapies. Here, we show that expression of the gluconeogenic isozyme fructose-1,6-bisphosphatase 2 (FBP2) is silenced in a broad spectrum of sarcoma subtypes, revealing an apparent common metabolic feature shared by diverse STSs. Enforced FBP2 expression inhibits sarcoma cell and tumor growth through two distinct mechanisms. First, cytosolic FBP2 antagonizes elevated glycolys  ...[more]

Similar Datasets

2019-09-20 | GSE137755 | GEO
| S-EPMC4162811 | biostudies-literature
| PRJNA566448 | ENA
| S-EPMC6400660 | biostudies-literature
| S-EPMC8157246 | biostudies-literature
| S-EPMC9977772 | biostudies-literature
| S-EPMC8127874 | biostudies-literature
| S-EPMC2720136 | biostudies-literature
| S-EPMC3249204 | biostudies-literature
| S-EPMC5412439 | biostudies-literature